ASBIS and Lanitis Group will invest €1.2 million to help fuel cancer biotech Theramir’s growth and expand its portfolio of stem cell and microRNA-based technologies

Cypriot biotech company Theramir, which is focused on the development of innovative targeted cancer therapeutics and diagnostics, announced today the closing of its latest funding round that welcomed two new strategic investors, ASBISc Enterprises Plc and the Lanitis Group.

The new investment will enable Theramir to advance the development of its proprietary therapeutic agents that leverage stem cell-derived extracellular vesicles and microRNAs (miRNAs) for the diagnosis and treatment of cancer.

View more here